

Supplemental Table Clinicopathological characteristics in 273 patients

Characteristic		upfront surgery		NACRT		p value
		n=124		n=149		
Gender, n, %	Male	73	58.9	87	58.4	0.936
	Female	51	41.1	62	41.6	
Age, n, %	<74	80	64.5	130	87.3	< 0.001
	≥75	44	35.5	19	12.8	
Resectability ^a , n, %	Resectable	104	83.9	98	65.8	< 0.001
	Borderline/URLA	20	16.1	51	34.2	
CA19-9, U/mL, range	Median (range)	88	(1-19296)	106	(1-4956)	0.258
DUPAN-2, U/mL, range	Median (range)	120	(25-1600)	160	(25-3980)	0.231
Operation time, min, range	Median (range)	297	(107-587)	294	(121-642)	0.765
Blood loss, mL, range	Median (range)	478	(10-3520)	365	(10-6730)	0.073
Pancreatic fistula ^b , n, %	≥ grade B ^a	34	27.9	24	16.1	0.026
pT status ^c , n, %	T1/T2	20	16.1	39	26.2	0.055
	T3/T4	104	83.9	110	73.8	
LN metastasis, n, %	Absent	58	46.8	114	76.5	< 0.001
	Present	66	53.2	35	23.5	
Resection status ^a , n, %	R0	100	80.7	140	94.0	< 0.001
	R1	24	19.4	9	6.0	
Adjuvant chemotherapy, n, %	Induction	105	84.7	139	93.3	< 0.001
	Completion	67	54.0	112	75.2	

^aNCCN Guidelines Version 2.2021. ^bDefined by International Study Group of Pancreatic Fistula.

^c7th edition of the Union for International Cancer Control TNM classification of malignant tumors.

NACRT indicates neoadjuvant chemoradiotherapy; CA19-9, carbohydrate antigen 19-9; DUPAN-2, Duke pancreatic mono-clonal antigen type 2c; pT status, pathological T status; LN, lymph node.